Equities

Chengdu Olymvax Biopharmaceuticals Inc

688319:SHH

Chengdu Olymvax Biopharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)8.19
  • Today's Change-0.22 / -2.62%
  • Shares traded887.50k
  • 1 Year change-53.17%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments356351439
Total Receivables, Net493495344
Total Inventory727975
Prepaid expenses4.192.352.28
Other current assets, total6.708.4415
Total current assets931936875
Property, plant & equipment, net449384281
Goodwill, net------
Intangibles, net20313938
Long term investments------
Note receivable - long term------
Other long term assets------
Total assets1,6131,4791,212
LIABILITIES
Accounts payable407634
Accrued expenses171930
Notes payable/short-term debt249035
Current portion long-term debt/capital leases3210.00--
Other current liabilities, total364331242
Total current liabilities476525342
Total long term debt182393.25
Total debt23813938
Deferred income tax2.722.562.30
Minority interest1410--
Other liabilities, total212020
Total liabilities696597367
SHAREHOLDERS EQUITY
Common stock406405405
Additional paid-in capital606581571
Retained earnings (accumulated deficit)(87)(105)(131)
Treasury stock - common(7.96)----
Unrealized gain (loss)------
Other equity, total------
Total equity917882845
Total liabilities & shareholders' equity1,6131,4791,212
Total common shares outstanding405405405
Treasury shares - common primary issue0.7500
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.